Join to View Full Profile
617 Eastlake Ave ESeattle, WA 98109
Phone+1 206-606-7348
Fax+1 206-606-1043
Dr. Cowan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- As an associate professor of medicine in the Div. of Medical Oncology at the University of Washington School of Medicine, my focus is in plasma cell disorders, specifically, MM and AL amyloidosis. I am involved in a variety of clinical research projects, both retrospective and prospective studies. I have a special interest in multiple myeloma and AL amyloidosis.
My clinical and research focus is on immunotherapy for MM, including CAR T cells; health services research in MM, and health informatics.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2012 - 2015
Boston University Medical CenterResidency, Internal Medicine, 2009 - 2011- Boston University Medical CenterInternship, Internal Medicine, 2008 - 2009
- University of Washington School of MedicineClass of 2008
Certifications & Licensure
AK State Medical License 2022 - 2026
WA State Medical License 2017 - 2025
MA State Medical License 2011 - 2013
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Start of enrollment: 2016 Aug 29
- A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma Start of enrollment: 2017 Nov 07
- A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2018 Apr 02
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsReal-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.Karthik Ramasamy, Ravi Vij, David Kuter, David Cella, Brian G M Durie
Clinical Lymphoma, Myeloma & Leukemia. 2025-05-01 - Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment.Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel Grajales-Cruz, Jack Khouri
Blood Advances. 2025-04-08 - A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up.Sherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, Andrew J Cowan, Gabriel O Cole
Blood. 2025-04-08
Abstracts/Posters
- A Phase 1, Open-Label, Multi-Center, Dose Escalation and Dose Expansion Study of NKTR-255 As a Single Agent in Relapsed or Refractory Hematologic Malignancies and in C...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Response to Bcma CAR-T Cells Correlates with Pretreatment Target Antigen Density and Is Improved By Small Molecule Inhibition of Gamma SecretaseAndrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Re...Andrew J. Cowan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Prolonged Lenalidomide Therapy in Multiple Myeloma Patients Does Not Impact Autologous PBSC Mobilization: A Single Center Retrospective Analysis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Multiple Myeloma Is Treatable, Not Curable. Is That Set to Change?April 3rd, 2025- Beyond BCMA-Directed CAR T-cell TherapyJune 21st, 2024
- Clinical Challenges: Quadruplet Therapy in Multiple MyelomaJune 1st, 2021
- Join now to see all
Grant Support
- T32 Oncology Training GrantNIH2014–2015
Committees
- Reviewer, Scientific Review Committee, FHCRC 2016 - Present
Professional Memberships
- Member
- Fellow
External Links
- HemOnc.orghttp://hemonc.org
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
